Toggle Side Panel

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

October 16, 2017 | Publication

The first randomized controlled data from cardiovascular outcomes trials with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have now been reported.1,2 This ESC/EAS Task Force met to consider the impact on practical guidance for the use of these novel agents. This updated clinical guidance provides novel clinical decision algorithms when considering a PCSK9 inhibitor, and monitoring treatment efficacy to statin, ezetimibe and PCSK9 inhibitor. Gaps in knowledge for PCSK9 inhibition are also discussed.

Cookies
We use cookies. If you think that's OK, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings".
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. You can change your settings from our Cookie Policy page.
Save Accept all

Report

Contains abusive or derogatory content
Contains mature or sensitive content
Contains misleading or false information
Contains spam, fake content or potential malware
Harassment or bullying behavior

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .